Vinyl sulfones: selective and tunable covalent warheads against challenging enzyme targets

Abstract

Over the past several decades there has been a growing recognition of the role that covalent drug candidates have played in the drug development process. With this recognition, compounds that are capable of selectively and irreversibly inactivating their targets through covalent bond formation are now being specifically designed rather than being serendipitously identified. Until recently, vinyl sulfones comprised only a small fraction of the warheads under development as covalent drug candidates, but an increasing number of compounds containing this versatile functional group are now under development and consideration as drug candidates. Vinyl sulfones are generally more reactive than structurally-related acrylamides and vinyl sulfonamides, presenting a challenge for producing target-specific inactivators. The most progress in overcoming this challenge has been made in designing vinyl sulfones as selective inactivators of microbial and human cysteine proteases, incorporating these reactive warheads into peptide and peptide mimetic structures that utilize the substrate recognition motifs of these proteases. However, effective vinyl sulfones have also been produced against a growing range of phosphoryl-utilizing enzymes including kinases, phosphatases and metabolic enzymes. Here, target selection takes advantage of the capability of the sulfonyl group to act as a phosphoryl mimic. An example of this approach is presented for the targeting of a metabolic enzyme, fungal aspartate semialdehyde dehydrogenase, an essential microbial enzyme in amino acid metabolism. The studies conducted to date demonstrate the potential utility of designing vinyl sulfone drug candidates to achieve selectivity against challenging and new drug-resistant targets.

Keywords

vinyl sulfone / covalent drug / phosphoryl mimetic / cysteine protease / enzyme inactivator / antifungal agent / aspartate semialdehyde dehydrogenase

References

[1] De Cesco S, Kurian J, Dufresne C, Mittermaier AK, Moitessier N. Covalent inhibitors design and discovery. Eur J Med Chem. 2017; 138: 96-114.

[2] Lee J, Park SB. Extended Applications of Small—Molecule Covalent Inhibitors toward Novel Therapeutic Targets. Pharmaceuticals (Basel). 2022; 15: 1478.

[3] Ahmadi R, Emami S. Recent applications of vinyl sulfone motif in drug design and discovery. Eur J Med Chem. 2022; 234: 114255.

[4] Kim G, Grams RJ, Hsu KL. Advancing Covalent Ligand and Drug Discovery beyond Cysteine. Chem Rev. 2025; 125: 6653-84.

[5] Xiao YC, Chen FE. The vinyl sulfone motif as a structural unit for novel drug design and discovery. Expert Opin Drug Discov. 2024; 19: 239-51.

[6] Meadows DC, Gervay—Hague J. Vinyl sulfones: synthetic preparations and medicinal chemistry applications. Med Res Rev. 2006; 26: 793-814.

[7] Alba AN, Companyó X, Rios R. Sulfones: new reagents in organocatalysis. Chem Soc Rev. 2010; 39: 2018-33.

[8] Yue WJ, Zhang CY, Yin L. Asymmetric Vinylogous Aldol—type Reactions of Aldehydes with Allyl Phosphonate and Sulfone. iScience. 2019; 14: 88-99.

[9] Flanagan ME, Abramite JA, Anderson DP, Aulabaugh A, Dahal UP, Gilbert AM, et al. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J Med Chem. 2014; 57: 10072—9.

[10] Gehringer M, Laufer SA. Emerging and Re—Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. J Med Chem. 2019; 62: 5673-724.

[11] Ábrányi—Balogh P, Petri L, Imre T, Szijj P, Scarpino A, Hrast M, et al. A road map for prioritizing warheads for cysteine targeting covalent inhibitors. Eur J Med Chem. 2018; 160: 94-107.

[12] Reddick JJ, Cheng J, Roush WR. Relative rates of Michael reactions of 2'—(phenethyl)thiol with vinyl sulfones, vinyl sulfonate esters, and vinyl sulfonamides relevant to vinyl sulfonyl cysteine protease inhibitors. Org Lett. 2003; 5: 1967—70.

[13] Friday SN, Koellner LA, Brown SW, Calbat CN, Curran CF, Dietz JD, et al. Development of Efficient Covalent Inactivators of a Fungal Aspartate Semialdehyde Dehydrogenase. Drug Dev Res. 2025; 86: e70095.

[14] Friday SN, Cheng DW, Zagler SG, Zanella BS, Dietz JD, Calbat CN, et al. Design and testing of selective inactivators against an antifungal enzyme target. Drug Dev Res. 2022; 83: 447-60.

[15] Friedman M, Cavins JF, Wall JS. Relative nucleophilic reactivities of amino groups and mercaptide ions in addition reactions with α,β—unsaturated compounds. J Amer Chem Soc. 1965; 87: 3672—82.

[16] Esterbauer H, Zollner H, Scholz N. Reaction of glutathione with conjugated carbonyls. Z Naturforsch C Biosci. 1975; 30: 466—73.

[17] Chan K, Poon R, O’Brien PJ. Application of structure—activity relationships to investigate the molecular mechanisms of hepatocyte toxicity and electrophilic reactivity of alpha,beta—unsaturated aldehydes. J Appl Toxicol. 2008; 28: 1027-39.

[18] Kathman SG, Xu Z, Statsyuk AV. A fragment—based method to discover irreversible covalent inhibitors of cysteine proteases. J Med Chem. 2014; 57: 4969—74.

[19] Choi DS, Kim YB, Lee YH, Cha SH, Sok DE. Glyceraldehyde—3—phosphate dehydrogenase as a biochemical marker of cytotoxicity by vinyl sulfones in cultured murine spleen lymphocytes. Cell Biol Toxicol. 1995; 11: 23-8.

[20] Regazzoni L, Colombo S, Mazzolari A, Vistoli G, Carini M. Serum albumin as a probe for testing the selectivity of irreversible cysteine protease inhibitors: The case of vinyl sulfones. J Pharm Biomed Anal. 2016; 124: 294-302.

[21] Li W, Yin Y, Yao H, Shuai W, Sun H, Xu S, et al. Discovery of novel vinyl sulfone derivatives as anti—tumor agents with microtubule polymerization inhibitory and vascular disrupting activities. Eur J Med Chem. 2018; 157: 1068-80.

[22] Choi JW, Kim S, Park JH, Kim HJ, Shin SJ, Kim JW, et al. Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2—Related Factor 2 (Nrf2) Activators for Parkinson’s Disease Therapy. J Med Chem. 2019; 62: 811-30.

[23] Aiebchun T, Mahalapbutr P, Auepattanapong A, Khaikate O, Seetaha S, Tabtimmai L, et al. Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies. Molecules. 2021; 26: 2211.

[24] Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, et al. Combined CRISPRi/a—Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule—Destabilizing Agent. Mol Cell. 2017; 68: 210-23.e6.

[25] Monfort—Vengut A, de Cárcer G. Lights and Shadows on the Cancer Multi—Target Inhibitor Rigosertib (ON—01910.Na). Pharmaceutics. 2023; 15: 1232.

[26] Kang AD, Cosenza SC, Bonagura M, Manair M, Reddy MV, Reddy EP. ON01210.Na (Ex—RAD®) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013; 8: e58355.

[27] Chen YT, Brinen LS, Kerr ID, Hansell E, Doyle PS, McKerrow JH, et al. In vitro and in vivo studies of the trypanocidal properties of WRR—483 against Trypanosoma cruzi. PLoS Negl Trop Dis. 2010; 4: e825.

[28] Jaishankar P, Hansell E, Zhao DM, Doyle PS, McKerrow JH, Renslo AR. Potency and selectivity of P2/P3—modified inhibitors of cysteine proteases from trypanosomes. Bioorg Med Chem Lett. 2008; 18: 624-8.

[29] Mellott DM, Tseng CT, Drelich A, Fajtová P, Chenna BC, Kostomiris DH, et al. A Clinical—Stage Cysteine Protease Inhibitor blocks SARS—CoV—2 Infection of Human and Monkey Cells. ACS Chem Biol. 2021; 16: 642-50.

[30] Rosenthal PJ, Olson JE, Lee GK, Palmer JT, Klaus JL, Rasnick D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob Agents Chemother. 1996; 40: 1600—3.

[31] Ettari R, Nizi E, Di Francesco ME, Dude MA, Pradel G, Vicík R, et al. Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain—2 inhibitors. J Med Chem. 2008; 51: 988-96.

[32] Zhang H, Collins J, Nyamwihura R, Ware S, Kaiser M, Ogungbe IV. Discovery of a quinoline—based phenyl sulfone derivative as an antitrypanosomal agent. Bioorg Med Chem Lett. 2018; 28: 1647-51.

[33] Zhang H, Collins J, Nyamwihura R, Crown O, Ajayi O, Ogungbe IV. Vinyl sulfone—based inhibitors of trypanosomal cysteine protease rhodesain with improved antitrypanosomal activities. Bioorg Med Chem Lett. 2020; 30: 127217.

[34] Dunny E, Doherty W, Evans P, Malthouse JP, Nolan D, Knox AJ. Vinyl sulfone—based peptidomimetics as anti—trypanosomal agents: design, synthesis, biological and computational evaluation. J Med Chem. 2013; 56: 6638—50.

[35] Chen YT, Lira R, Hansell E, McKerrow JH, Roush WR. Synthesis of macrocyclic trypanosomal cysteine protease inhibitors. Bioorg Med Chem Lett. 2008; 18: 5860—3.

[36] Ghoshal A, Asressu KH, Hossain MA, Brown PJ, Nandakumar M, Vala A, et al. Structure Activity of β—Amidomethyl Vinyl Sulfones as Covalent Inhibitors of Chikungunya nsP2 Cysteine Protease with Antialphavirus Activity. J Med Chem. 2024; 67: 16505—32.

[37] Kish MM, Viola RE. Oxyanion Specificity of Aspartate—beta—semialdehyde Dehydrogenase. Inorg Chem. 1999; 38: 818-20.

[38] Anscombe E, Meschini E, Mora—Vidal R, Martin MP, Staunton D, Geitmann M, et al. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chem Biol. 2015; 22: 1159-64.

[39] Liu S, Zhou B, Yang H, He Y, Jiang ZX, Kumar S, et al. Aryl vinyl sulfonates and sulfones as active site—directed and mechanism—based probes for protein tyrosine phosphatases. J Am Chem Soc. 2008; 130: 8251-60.

[40] Hong BV, Lee JH, Rice RH. Off—target effects of protein tyrosine phosphatase inhibitors on oncostatin M—treated human epidermal keratinocytes: the phosphatase targeting STAT1 remains unknown. PeerJ. 2020; 8: e9504.

[41] Hong SH, Xi SY, Johns AC, Tang LC, Li A, Hum MN, et al. Mapping the Chemical Space of Active—Site Targeted Covalent Ligands for Protein Tyrosine Phosphatases. Chembiochem. 2023; 24: e202200706.

[42] Ruddraraju KV, Zhang ZY. Covalent inhibition of protein tyrosine phosphatases. Mol Biosyst. 2017; 13: 1257-79.

[43] Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024; 24: e428—38.

[44] Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012; 4: 165rv13.

[45] Viola RE. The central enzymes of the aspartate family of amino acid biosynthesis. Acc Chem Res. 2001; 34: 339-49.

[46] Gerdes SY, Scholle MD, Campbell JW, Balázsi G, Ravasz E, Daugherty MD, et al. Experimental determination and system level analysis of essential genes in Escherichia coli MG1655. J Bacteriol. 2003; 185: 5673—84.

[47] Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, Arnaud M, et al. Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A. 2003; 100: 4678-83.

[48] Blanco J, Moore RA, Viola RE. Capture of an intermediate in the catalytic cycle of L—aspartate—beta—semialdehyde dehydrogenase. Proc Natl Acad Sci U S A. 2003; 100: 12613-7.

[49] Viola RE, Faehnle CR, Blanco J, Moore RA, Liu X, Arachea BT, et al. The catalytic machinery of a key enzyme in amino Acid biosynthesis. J Amino Acids. 2011; 2011: 352538.

[50] Kikuchi S, Green JC, Rogness DC, Lam B, Owyang ZA, Malmstrom RD, et al. Identification of VVD—214/RO7589831, a Clinical—Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI—High Cancers. J Med Chem. 2025; 68: 25912—38.

[51] Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh H. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A. 1997; 94: 6629—34.

[52] Ettari R, Bonaccorso C, Micale N, Heindl C, Schirmeister T, Calabrò ML, et al. Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors. ChemMedChem. 2011; 6: 1228—37.

[53] Yu CH, Chou CC, Lee DY, Khoo KH, Chang GD. Target identification reveals protein arginine methyltransferase 1 is a potential target of phenyl vinyl sulfone and its derivatives. Biosci Rep. 2018; 38: BSR20171717.

[54] Jung S, Fuchs N, Johe P, Wagner A, Diehl E, Yuliani T, et al. Fluorovinylsulfones and —Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure—Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies. J Med Chem. 2021; 64: 12322—58.

[55] Pan S, Jang SY, Liew SS, Fu J, Wang D, Lee JS, et al. A Vinyl Sulfone—Based Fluorogenic Probe Capable of Selective Labeling of PHGDH in Live Mammalian Cells. Angew Chem Int Ed Engl. 2018; 57: 579-83.

[56] Mertens MD, Schmitz J, Horn M, Furtmann N, Bajorath J, Mareš M, et al. A coumarin—labeled vinyl sulfone as tripeptidomimetic activity—based probe for cysteine cathepsins. Chembiochem. 2014; 15: 955-9.

[57] Zhang T, Cai J, Wang H, Wang M, Yuan H, Wu Z, et al. RXH—Reactive¹⁸F—Vinyl Sulfones as Versatile Agents for PET Probe Construction. Bioconjug Chem. 2020; 31: 2482—7.

[58] Morales—Sanfrutos J, Lopez—Jaramillo FJ, Hernandez—Mateo F, Santoyo—Gonzalez F. Vinyl sulfone bifunctional tag reagents for single—point modification of proteins. J Org Chem. 2010; 75: 4039-47.

[59] Lemke C, Jílková A, Ferber D, Braune A, On A, Johe P, et al. Two Tags in One Probe: Combining Fluorescence— and Biotin—based Detection of the Trypanosomal Cysteine Protease Rhodesain. Chemistry. 2022; 28: e202201636.

[60] Li YD, Ma MW, Hassan MM, Hunkeler M, Teng M, Puvar K, et al. Template—assisted covalent modification underlies activity of covalent molecular glues. Nat Chem Biol. 2024; 20: 1640—9.

[61] Krantz A. Classification of enzyme inhibitors. Bioorg Med Chem Lett. 1992; 2: 1327—34.